Patients with lower (< 50% vs. ≥ 50%) bone marrow blasts (66.7% vs. 33.3%) at diagnosis and de novo CML-MBP (80% vs. 46.2%) were more likely to achieve hematologic response whereas complex cytogenetics (57.1% vs. 54.6%) or poor genetic risk (61.5% vs. 40%) did not seem to affect response. The gene discussed is MBP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.